NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Ownership - Who owns Vistagen Therapeutics?

Insider buying vs selling

Have Vistagen Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joshua S. PrinceChief Operating Officer2025-12-314,386$0.56
$2.47kBuy
Reid G. AdlerChief Legal Officer2025-06-307,541$1.70
$12.82kBuy
Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER2025-06-306,617$1.70
$11.25kBuy
Joshua S. PrinceChief Operating Officer2025-06-304,882$1.70
$8.30kBuy
Shawn SinghPresident and CEO2025-06-307,541$1.70
$12.82kBuy

1 of 1

VTGN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VTGN insiders and whales buy or sell their stock.

VTGN Shareholders

What type of owners hold Vistagen Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Venrock Healthcare Capital Partners II LP52.25%20,637,286$14.86MInsider
Janus Henderson Group PLC10.55%4,165,767$3.00MInstitution
Holding Co Cato8.38%3,310,836$2.38MInsider
Orbimed Advisors LLC7.75%3,060,000$2.20MInstitution
Tcg Crossover Management LLC6.78%2,676,580$1.93MInstitution
Stempoint Capital LP6.30%2,488,685$1.79MInstitution
Nantahala Capital Management LLC5.01%1,978,492$1.42MInstitution
Vanguard Group Inc4.27%1,687,735$1.22MInstitution
Commodore Capital LP3.99%1,575,000$1.13MInstitution
Platinum Long Term Growth VII LLC3.95%1,558,862$1.12MInsider

1 of 3

VTGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VTGN45.78%54.22%Net BuyingNet Buying
ATHA12.29%87.71%Net BuyingNet Buying
BRNS22.46%53.40%
HYPD3.63%96.37%Net BuyingNet Buying
IGC5.86%21.67%

Vistagen Therapeutics Stock Ownership FAQ

Who owns Vistagen Therapeutics?

Vistagen Therapeutics (NASDAQ: VTGN) is owned by 59.16% institutional shareholders, 70.06% Vistagen Therapeutics insiders, and 0.00% retail investors. Venrock Healthcare Capital Partners II LP is the largest individual Vistagen Therapeutics shareholder, owning 20.64M shares representing 52.25% of the company. Venrock Healthcare Capital Partners II LP's Vistagen Therapeutics shares are currently valued at $15.27M.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.